(Q35570981)

8 August 2017

title

Antihypertensive therapy: special focus on drug interactions (English)

1 reference

8 August 2017

Renke Maas

1

1 reference

8 August 2017

Rainer H. Böger

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14585065

26 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

http://www.tandfonline.com/doi/pdf/10.1517/14740338.2.6.549

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Expert Opinion on Drug Safety

26 March 2024

published in

1 reference

8 August 2017

volume

2

1 reference

8 August 2017

issue

6

1 reference

8 August 2017

page(s)

549-579

1 reference

Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Characteristics of patients with uncontrolled hypertension in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Age-dependent changes of the kidneys: pharmacological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Renal dysfunction complicating the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

A rational approach to the selection of useful drugs for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Misconceptions of older adults with hypertension concerning OTC medications and alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Rifampin and rifabutin drug interactions: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Molecular basis of ethnic differences in drug disposition and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Interindividual variability in inhibition and induction of cytochrome P450 enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Cerivastatin and reports of fatal rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Inheritance and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Pharmacogenetics and the practice of medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Implications of cytochrome P450 interactions when prescribing medication for hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Effects of food on clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Influence of Food Intake on Presystemic Clearance of Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Grapefruit juice-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Pharmacokinetic interactions between herbal remedies and medicinal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

St John's Wort supplements endanger the success of organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Cardiovascular toxicity after ingestion of "herbal ecstacy".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Metabolism of carteolol by cDNA-expressed human cytochrome P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Pharmacology of nebivolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Screening drugs for metabolic stability using pulsed ultrafiltration mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

The interaction of diltiazem with simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Interaction of citrus juices with felodipine and nifedipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Interaction of digoxin with antihypertensive drugs via MDR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Role of transport proteins in drug absorption, distribution and excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Acute hemodynamic and electrophysiologic effects and safety of high-dose intravenous diltiazem in patients receiving metoprolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Sinus arrest caused by atenolol-verapamil combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Nifedipine and beta-blockade as a cause of cardiac failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Rapid clonidine withdrawal with blood pressure overshoot exaggerated by beta-blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Haemodynamic effects of pretreatment with metoprolol in hypertensive patients undergoing surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Beneficial effects from beta-adrenergic blockade in elderly patients undergoing noncardiac surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Effect of beta-adrenoreceptor blockade with nadolol on the duration of local anesthesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Cocaine-induced myocardial ischemia and infarction: pathophysiology, recognition, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

The interactions between nisoldipine and two beta-adrenoceptor antagonists-atenolol and propranolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Atenolol interaction with aspirin, allopurinol, and ampicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Effect of food on the bioavailability of labetalol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Pharmacokinetic drug interactions with amiodarone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Adverse interaction between clonidine and verapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide acetate and verapamil: effects on cardiac function and drug clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Rhabdomyolysis with concurrent atorvastatin and diltiazem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Clinically relevant differences between the statins: implications for therapeutic selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Diltiazem-cyclosporin pharmacokinetic interaction--dose-response relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Associations between use of cyclosporine-sparing agents and outcome in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Eprosartan: a review of its use in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Telmisartan: a review of its use in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Angiotensin II receptor blockers for the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Comment--Val-HeFT and angiotensin-receptor blockers in perspective: A tale of the blind man and the elephant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Repeated transient anuria following losartan administration in a patient with a solitary kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Lithium intoxication in an elderly patient after combined treatment with losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Clinical pharmacokinetics of fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Drug interactions with irbesartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Pharmacokinetics of valsartan in patients with liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

The appropriateness of drug use in an older nondemented and demented population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Diuretic therapy for hypertension and the risk of primary cardiac arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

The effects of sulindac and indomethacin on the anti-hypertensive and diuretic action of hydrochlorothiazide in patients with mild to moderate essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Effects of low-dose aspirin on responses to furosemide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Interaction between nonsteroidal anti-inflammatory drug intake and calcium-channel blocker-based antihypertensive treatment in the Syst-Eur trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Ototoxicity induced by gentamicin and furosemide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Effect of furosemide on aminoglycoside-induced nephrotoxicity and auditory toxicity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Lithium toxicity induced by triamterene-hydrochlorothiazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Differential pharmacokinetics of lithium in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Effect of food on the absorption of frusemide and bumetanide in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Furosemide-probenecid interaction as a laboratory exercise for undergraduate education in clinical pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Rapid life-threatening hyperkalemia after addition of amiloride HCl/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Guidelines for the diagnosis and treatment of chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Captopril augments both basal and frusemide‐induced natriuresis in normal man by suppression of circulating angiotensin II

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Should the angiotensin II antagonists be discontinued before surgery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Possible interaction of clozapine and lisinopril

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Pharmacokinetic drug interactions with ACE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Doxazosin and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Immediate cardiovascular responses to oral prazosin--effects of concurrent beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Acute hypotensive response to nifedipine added to prazosin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Effects of grapefruit juice and smoking on verapamil concentrations in steady state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Adverse interaction between beta-adrenergic blocking drugs and verapamil--report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Elevated serum carbamazepine concentrations following diltiazem initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Carbamazepine decreases antihypertensive effect of nilvadipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Diltiazem increases steady state digoxin serum levels in patients with cardiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretion of digitoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Pharmacoepidemiologic detection of calcium channel blocker-induced change on digoxin clearance using multiple trough screen analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Influence of nisoldipine on haemodynamic effects and plasma levels of digoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Dose of midazolam should be reduced during diltiazem and verapamil treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Compound cardiac toxicity of oral erythromycin and verapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

A population-based European cohort study of persistence in newly diagnosed hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Pharmacogenetics and future drug development and delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Comparison of nifedipine alone and with diltiazem or verapamil in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Tachycardia, orthostatic hypotension and profound weakness due to concomitant use of fluoxetine and nifedipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Marked Increase of Venlafaxine Enantiomer Concentrations as a Consequence of Metabolic Interactions: A Case Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

J-Shaped Relation Between Blood Pressure and Stroke in Treated Hypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.6.549

Inadequate Management of Blood Pressure in a Hypertensive Population

21 January 2018

4

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Hypertension in high-risk patients: beware of the underuse of effective combination therapy (results of the PRATIK study)

26 March 2024

5

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Comorbidity and drug use in cognitively impaired elderly living in long-term care

26 March 2024

6

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

The extent of potential antihypertensive drug interactions in a Medicaid population

26 March 2024

10

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Hospital admissions due to adverse drug reactions: a comparative study from Jerusalem and Berlin

26 March 2024

12

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Potential risks and prevention, Part 1: Fatal adverse drug events.

26 March 2024

13

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril

26 March 2024

19

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping.

26 March 2024

27

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

What lessons can be learnt from withdrawal of mibefradil from the market?

26 March 2024

32

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients

26 March 2024

42

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Acute heart transplant rejection due to Saint John's wort

26 March 2024

46

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Journal of Pharmaceutical Sciences

26 March 2024

48

5

185

FOSTER BC

2002

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

St John's Wort: effect on CYP3A4 activity

26 March 2024

50

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4

26 March 2024

52

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

26 March 2024

58

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Comparison of Verapamil, Diltiazem, and Labetalol on the Bioavailability and Metabolism of Imipramine

26 March 2024

64

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes

26 March 2024

66

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation

26 March 2024

68

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Erythromycin-felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice*

26 March 2024

79

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Drug Metabolism and Disposition

26 March 2024

82

29

1316

NARITOMI Y

2001

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics

26 March 2024

83

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans.

26 March 2024

87

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein

26 March 2024

88

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil

26 March 2024

90

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers

26 March 2024

95

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Interaction between oral verapamil and beta-blockers during submaximal exercise: relevance of ancillary properties

26 March 2024

97

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Interaction between timolol eyedrops and oral nicardipine or oral diltiazem in healthy Japanese subjects

26 March 2024

99

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Hypertensive response to propranolol in a patient treated with methyldopa-a proposed mechanism

26 March 2024

102

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Effect of naproxen and sulindac on blood pressure response to atenolol

26 March 2024

104

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Haemodynamic effects and kinetics of concomitant intravenous disopyramide and atenolol in patients with ischaemic heart disease

26 March 2024

116

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

The potential for drug interactions with statin therapy in Ireland

26 March 2024

125

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Drug interactions of the statins and consequences for drug selection.

26 March 2024

126

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations

26 March 2024

128

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Absence of a dose-response of cyclosporine levels to clinically used doses of diltiazem and verapamil

26 March 2024

133

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Pharmacokinetic interactions between microemulsion formulated cyclosporine A and diltiazem in renal transplant recipients

26 March 2024

134

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Nifedipine interaction with tacrolimus in liver transplant recipients

26 March 2024

136

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Lithium intoxication after administration of AT1 blockers

26 March 2024

149

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists

26 March 2024

151

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers

26 March 2024

154

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists

26 March 2024

158

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Diuretic-induced hypokalemia

26 March 2024

161

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction

26 March 2024

162

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Drug utilisation in Dutch nursing homes

26 March 2024

165

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Hypokalemic paralysis in furosemide therapy and simultaneous laxative abuse

26 March 2024

166

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure

26 March 2024

170

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil

26 March 2024

176

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Diuretic-induced lithium toxicity presenting as mania

26 March 2024

182

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Nine cases of torsade de pointes with bepridil administration

26 March 2024

183

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis

26 March 2024

185

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Blunting of furosemide diuresis by aspirin in man

26 March 2024

186

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Malabsorption of frusemide caused by phenytoin

26 March 2024

191

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

The influence of nonsteroidal anti-inflammatory drugs and probenecid on the renal response to and kinetics of piretanide in man.

26 March 2024

194

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Spironolactone-induced changes in digoxin kinetics

26 March 2024

195

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure

26 March 2024

198

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction.

26 March 2024

206

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial

26 March 2024

210

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients

26 March 2024

211

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

A case of lisinopril-induced lithium toxicity

26 March 2024

213

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients

26 March 2024

219

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Doxazosin and congestive heart failure

26 March 2024

221

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Interaction of alcohol and an alpha1-blocker on ambulatory blood pressure in patients with essential hypertension

26 March 2024

222

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

The combination of prazosin and verapamil in the treatment of essential hypertension

26 March 2024

223

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Combined alpha adrenoceptor antagonism and calcium channel blockade in normal subjects

26 March 2024

226

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil

26 March 2024

227

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers

26 March 2024

228

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Drug Metabolism and Disposition

26 March 2024

231

29

1284

KOSUGE K

2001

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol

26 March 2024

234

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

The influence of verapamil on serum digoxin concentration

26 March 2024

242

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Grapefruit juice--felodipine interaction in the elderly

26 March 2024

245

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Erythromycin-felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice*

26 March 2024

247

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

The effect of three different oral doses of verapamil on the disposition of theophylline

26 March 2024

251

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Verapamil inhibits ethanol elimination and prolongs the perception of intoxication

26 March 2024

253

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Control of hypertension--an important national priority

26 March 2024

257

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

26 March 2024

263

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Reporting of adverse events

26 March 2024

264

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Polymorphism of CYP2D6 in Black populations: implications for psychopharmacology

26 March 2024

266

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial

26 March 2024

268

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients

26 March 2024

270

1 reference

https://api.crossref.org/works/10.1517/14740338.2.6.549

26 March 2024

Identifiers

1 reference

8 August 2017

1 reference